Travere Therapeutics (TVTX) Property, Plant & Equipment (Net) (QoQ) (2013 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.82% |
| Dec 31, 2025 | -6.90% |
| Sep 30, 2025 | -5.28% |
| Jun 30, 2025 | -6.02% |
| Mar 31, 2025 | -9.05% |
| Dec 31, 2024 | -13.40% |
| Sep 30, 2024 | -6.35% |
| Jun 30, 2024 | -5.23% |
| Mar 31, 2024 | -7.17% |
| Dec 31, 2023 | -6.47% |
| Sep 30, 2023 | -6.70% |
| Jun 30, 2023 | -6.10% |
| Mar 31, 2023 | 0.86% |
| Dec 31, 2022 | -5.32% |
| Sep 30, 2022 | -5.19% |
| Jun 30, 2022 | -4.92% |
| Mar 31, 2022 | -4.54% |
| Dec 31, 2021 | -3.54% |
| Sep 30, 2021 | -1.77% |
| Jun 30, 2021 | 0.20% |
| Mar 31, 2021 | 24.20% |
| Dec 31, 2020 | 65.34% |
| Sep 30, 2020 | 94.40% |
| Jun 30, 2020 | 11.96% |
| Mar 31, 2020 | -9.48% |
| Dec 31, 2019 | -0.65% |
| Sep 30, 2019 | -3.48% |
| Jun 30, 2019 | 0.67% |
| Mar 31, 2019 | -4.80% |
| Dec 31, 2018 | -5.33% |
| Sep 30, 2018 | -3.82% |
| Jun 30, 2018 | 13.58% |
| Mar 31, 2018 | -5.82% |
| Dec 31, 2017 | 18.88% |
| Sep 30, 2017 | 6.97% |
| Jun 30, 2017 | 4.61% |
| Mar 31, 2017 | -6.15% |
| Dec 31, 2016 | 577.23% |
| Sep 30, 2016 | 0.26% |
| Jun 30, 2016 | -8.63% |
| Mar 31, 2016 | -2.57% |
| Dec 31, 2015 | -10.46% |
| Sep 30, 2015 | -6.09% |
| Jun 30, 2015 | -17.72% |
| Mar 31, 2015 | -7.81% |
| Dec 31, 2014 | 5.98% |
| Dec 31, 2013 | 231.52% |